Clinical trial
Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in…
NCT00145145 · Ludwig Institute for Cancer Research, Other · Terminated
Key facts
| NCT number | NCT00145145 |
|---|---|
| Title | Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma |
| Official title | Phase I/II Study of Immunization With the MAGE-3.A1 Peptide Mixed With the Immunological Adjuvant CpG 7909 in Patients With Metastatic Melanoma |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Biological |
| Interventions | MAGE-3.A1 peptide and CpG 7909 |
| Enrollment | 1 |
| Start date | Jan 12, 2005 |
| Primary completion | Apr 7, 2005 |
| Completion | Apr 28, 2008 |
| First posted | Sep 5, 2005 |
| Last update posted | Oct 7, 2022 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: